• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

SARS-CoV-2 刺突变异株的中和抗性主要由协同受体结合域取代介导。

Neutralisation resistance of SARS-CoV-2 spike-variants is primarily mediated by synergistic receptor binding domain substitutions.

机构信息

Copenhagen Hepatitis C Program (CO-HEP), Department of Infectious Diseases, Copenhagen University Hospital, Hvidovre, Denmark.

Copenhagen Hepatitis C Program (CO-HEP), Department of Immunology and Microbiology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.

出版信息

Emerg Microbes Infect. 2024 Dec;13(1):2412643. doi: 10.1080/22221751.2024.2412643. Epub 2024 Nov 13.

DOI:10.1080/22221751.2024.2412643
PMID:39392057
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11562025/
Abstract

The evolution of SARS-CoV-2 has led to the emergence of numerous variants of concern (VOCs), marked by changes in the viral spike glycoprotein, the primary target for neutralising antibody (nAb) responses. Emerging VOCs, particularly omicron sub-lineages, show resistance to nAbs induced by prior infection or vaccination. The precise spike protein changes contributing to this resistance remain unclear in infectious cell culture systems. In the present study, a large panel of infectious SARS-CoV-2 mutant viruses, each with spike protein changes found in VOCs, including omicron JN.1 and its derivatives KP.2 and KP.3, was generated using a reverse genetic system. The susceptibility of these viruses to antibody neutralisation was measured using plasma from convalescent and vaccinated individuals. Synergistic roles of combined substitutions in the spike receptor binding domain (RBD) were observed in neutralisation resistance. However, recombinant viruses with the entire spike protein from a specific VOC showed enhanced resistance, indicating that changes outside the RBD are also significant. analyses of spike antibody epitopes suggested that changes in neutralisation could be due to altered antibody binding affinities. Assessing ACE2 usage for entry through anti-ACE2 antibody blocking and ACE2 siRNA revealed that omicron BA.2.86 and JN.1 mutant viruses were less dependent on ACE2 for entry. However, surface plasmon resonance analysis showed increased affinity for ACE2 for both BA.2.86 and JN.1 compared to the ancestral spike. This detailed analysis of specific changes in the SARS-CoV-2 spike enhances understanding of coronavirus evolution, particularly regarding neutralising antibody evasion and ACE2 entry receptor dependence.

摘要

SARS-CoV-2 的进化导致了众多关注的变异株(VOCs)的出现,这些变异株的特征是病毒刺突糖蛋白发生了变化,这是中和抗体(nAb)反应的主要目标。新兴的 VOCs,特别是奥密克戎亚系,显示出对先前感染或接种诱导的 nAb 的抗性。在感染细胞培养系统中,导致这种抗性的确切刺突蛋白变化仍不清楚。在本研究中,使用反向遗传系统生成了一大组具有 VOC 中发现的刺突蛋白变化的传染性 SARS-CoV-2 突变病毒,包括奥密克戎 JN.1 及其衍生株 KP.2 和 KP.3。使用恢复期和接种疫苗个体的血浆测量这些病毒对抗体中和的敏感性。在 RBD 中观察到组合取代的协同作用在中和抗性中。然而,具有特定 VOC 整个刺突蛋白的重组病毒显示出增强的抗性,表明 RBD 之外的变化也很重要。对刺突抗体表位的分析表明,中和变化可能是由于抗体结合亲和力的改变。通过抗 ACE2 抗体阻断和 ACE2 siRNA 评估 ACE2 用于进入的作用,发现奥密克戎 BA.2.86 和 JN.1 突变病毒对进入的依赖程度较低。然而,表面等离子体共振分析显示,与原始刺突相比,BA.2.86 和 JN.1 对 ACE2 的亲和力增加。对 SARS-CoV-2 刺突中特定变化的详细分析增强了对冠状病毒进化的理解,特别是关于中和抗体逃逸和 ACE2 进入受体的依赖。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2094/11562025/0ea6081c7a59/TEMI_A_2412643_F0006_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2094/11562025/b33256dcd323/TEMI_A_2412643_F0001_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2094/11562025/577d5698eaee/TEMI_A_2412643_F0002_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2094/11562025/1e979bf249ea/TEMI_A_2412643_F0003_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2094/11562025/bafe6f22eaaf/TEMI_A_2412643_F0004_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2094/11562025/85f86a92f493/TEMI_A_2412643_F0005_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2094/11562025/0ea6081c7a59/TEMI_A_2412643_F0006_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2094/11562025/b33256dcd323/TEMI_A_2412643_F0001_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2094/11562025/577d5698eaee/TEMI_A_2412643_F0002_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2094/11562025/1e979bf249ea/TEMI_A_2412643_F0003_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2094/11562025/bafe6f22eaaf/TEMI_A_2412643_F0004_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2094/11562025/85f86a92f493/TEMI_A_2412643_F0005_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2094/11562025/0ea6081c7a59/TEMI_A_2412643_F0006_OC.jpg

相似文献

1
Neutralisation resistance of SARS-CoV-2 spike-variants is primarily mediated by synergistic receptor binding domain substitutions.SARS-CoV-2 刺突变异株的中和抗性主要由协同受体结合域取代介导。
Emerg Microbes Infect. 2024 Dec;13(1):2412643. doi: 10.1080/22221751.2024.2412643. Epub 2024 Nov 13.
2
AlphaFold2 Modeling and Molecular Dynamics Simulations of the Conformational Ensembles for the SARS-CoV-2 Spike Omicron JN.1, KP.2 and KP.3 Variants: Mutational Profiling of Binding Energetics Reveals Epistatic Drivers of the ACE2 Affinity and Escape Hotspots of Antibody Resistance.AlphaFold2 对 SARS-CoV-2 刺突奥密克戎 JN.1、KP.2 和 KP.3 变体构象集合的建模和分子动力学模拟:结合能突变分析揭示 ACE2 亲和力的上位驱动因素和抗体耐药性逃逸热点。
Viruses. 2024 Sep 13;16(9):1458. doi: 10.3390/v16091458.
3
Characterization of Entry Pathways, Species-Specific Angiotensin-Converting Enzyme 2 Residues Determining Entry, and Antibody Neutralization Evasion of Omicron BA.1, BA.1.1, BA.2, and BA.3 Variants.刺突蛋白结构特征、决定病毒进入宿主细胞的物种特异性血管紧张素转换酶 2 残基,以及奥密克戎 BA.1、BA.1.1、BA.2 和 BA.3 变异株的抗体中和逃逸。
J Virol. 2022 Sep 14;96(17):e0114022. doi: 10.1128/jvi.01140-22. Epub 2022 Aug 24.
4
Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants.通过 SARS-CoV-2 刺突蛋白变体逃避中和抗体。
Elife. 2020 Oct 28;9:e61312. doi: 10.7554/eLife.61312.
5
Omicron-specific ultra-potent SARS-CoV-2 neutralizing antibodies targeting the N1/N2 loop of Spike N-terminal domain.针对 Spike N 端结构域 N1/N2 环的奥密克戎特异性超强 SARS-CoV-2 中和抗体。
Emerg Microbes Infect. 2024 Dec;13(1):2412990. doi: 10.1080/22221751.2024.2412990. Epub 2024 Oct 28.
6
Epitope Classification and RBD Binding Properties of Neutralizing Antibodies Against SARS-CoV-2 Variants of Concern.针对关注的 SARS-CoV-2 变体的中和抗体的表位分类和 RBD 结合特性。
Front Immunol. 2021 Jun 4;12:691715. doi: 10.3389/fimmu.2021.691715. eCollection 2021.
7
Structural basis for the evolution and antibody evasion of SARS-CoV-2 BA.2.86 and JN.1 subvariants.SARS-CoV-2 BA.2.86 和 JN.1 亚变种的进化和抗体逃逸的结构基础。
Nat Commun. 2024 Sep 4;15(1):7715. doi: 10.1038/s41467-024-51973-8.
8
Mutations in the SARS-CoV-2 spike receptor binding domain and their delicate balance between ACE2 affinity and antibody evasion.SARS-CoV-2 刺突受体结合域的突变及其在与 ACE2 亲和力和抗体逃逸之间的微妙平衡。
Protein Cell. 2024 May 28;15(6):403-418. doi: 10.1093/procel/pwae007.
9
Recurrent SARS-CoV-2 spike mutations confer growth advantages to select JN.1 sublineages.复发性严重急性呼吸综合征冠状病毒2(SARS-CoV-2)刺突突变赋予选定的JN.1亚谱系生长优势。
Emerg Microbes Infect. 2024 Dec;13(1):2402880. doi: 10.1080/22221751.2024.2402880. Epub 2024 Sep 16.
10
Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant.识别 SARS-CoV-2 刺突蛋白主要和次要表位的单克隆抗体的中和效力受 B.1.1.7 变异株的影响。
Immunity. 2021 Jun 8;54(6):1276-1289.e6. doi: 10.1016/j.immuni.2021.03.023. Epub 2021 Apr 1.

引用本文的文献

1
SARS-CoV-2 Remdesivir Exposure Leads to Different Evolutionary Pathways That Converge in Moderate Levels of Drug Resistance.严重急性呼吸综合征冠状病毒2(SARS-CoV-2)接触瑞德西韦会导致不同的进化途径,这些途径在中等水平的耐药性上趋同。
Viruses. 2025 Jul 29;17(8):1055. doi: 10.3390/v17081055.
2
Spike substitutions E484D, P812R and Q954H mediate ACE2-independent entry of SARS-CoV-2 across different cell lines.刺突蛋白替代物E484D、P812R和Q954H介导新冠病毒在不同细胞系中不依赖血管紧张素转换酶2(ACE2)的进入。
PLoS One. 2025 Aug 1;20(8):e0326419. doi: 10.1371/journal.pone.0326419. eCollection 2025.
3
T cell receptor usage and epitope specificity amongst CD8 and CD4 SARS-CoV-2-specific T cells.

本文引用的文献

1
Fast evolution of SARS-CoV-2 BA.2.86 to JN.1 under heavy immune pressure.在强大免疫压力下,新冠病毒BA.2.86快速进化为JN.1 。
Lancet Infect Dis. 2024 Feb;24(2):e70-e72. doi: 10.1016/S1473-3099(23)00744-2. Epub 2023 Dec 15.
2
Antigenicity and receptor affinity of SARS-CoV-2 BA.2.86 spike.SARS-CoV-2 BA.2.86 刺突蛋白的抗原性和受体亲和力。
Nature. 2023 Dec;624(7992):639-644. doi: 10.1038/s41586-023-06750-w. Epub 2023 Oct 23.
3
Neutralization, effector function and immune imprinting of Omicron variants.奥密克戎变异株的中和作用、效应功能和免疫印迹。
新冠病毒特异性CD8和CD4 T细胞中的T细胞受体使用情况及表位特异性
Front Immunol. 2025 Feb 28;16:1510436. doi: 10.3389/fimmu.2025.1510436. eCollection 2025.
Nature. 2023 Sep;621(7979):592-601. doi: 10.1038/s41586-023-06487-6. Epub 2023 Aug 30.
4
TMEM106B is a receptor mediating ACE2-independent SARS-CoV-2 cell entry.TMEM106B 是一种受体,可介导 ACE2 非依赖的 SARS-CoV-2 细胞进入。
Cell. 2023 Aug 3;186(16):3427-3442.e22. doi: 10.1016/j.cell.2023.06.005. Epub 2023 Jul 7.
5
Durability and breadth of neutralisation following multiple antigen exposures to SARS-CoV-2 infection and/or COVID-19 vaccination.多次接触 SARS-CoV-2 感染和/或 COVID-19 疫苗后的持久性和中和广度。
EBioMedicine. 2023 Mar;89:104475. doi: 10.1016/j.ebiom.2023.104475. Epub 2023 Mar 2.
6
Neutralization of BA.4-BA.5, BA.4.6, BA.2.75.2, BQ.1.1, and XBB.1 with Bivalent Vaccine.用二价疫苗中和BA.4-BA.5、BA.4.6、BA.2.75.2、BQ.1.1和XBB.1
N Engl J Med. 2023 Mar 2;388(9):854-857. doi: 10.1056/NEJMc2214916. Epub 2023 Jan 25.
7
SARS-CoV-2 variant biology: immune escape, transmission and fitness.SARS-CoV-2 变体生物学:免疫逃逸、传播和适应性。
Nat Rev Microbiol. 2023 Mar;21(3):162-177. doi: 10.1038/s41579-022-00841-7. Epub 2023 Jan 18.
8
Imprinted SARS-CoV-2 humoral immunity induces convergent Omicron RBD evolution.印迹 SARS-CoV-2 体液免疫诱导奥密克戎 RBD 进化趋同。
Nature. 2023 Feb;614(7948):521-529. doi: 10.1038/s41586-022-05644-7. Epub 2022 Dec 19.
9
Low neutralization of SARS-CoV-2 Omicron BA.2.75.2, BQ.1.1 and XBB.1 by parental mRNA vaccine or a BA.5 bivalent booster.原始mRNA疫苗或BA.5二价加强针 对SARS-CoV-2奥密克戎BA.2.75.2、BQ.1.1和XBB.1的中和作用较低。
Nat Med. 2023 Feb;29(2):344-347. doi: 10.1038/s41591-022-02162-x. Epub 2022 Dec 6.
10
Broadly neutralizing antibodies to SARS-CoV-2 and other human coronaviruses.广谱中和抗体对 SARS-CoV-2 和其他人类冠状病毒。
Nat Rev Immunol. 2023 Mar;23(3):189-199. doi: 10.1038/s41577-022-00784-3. Epub 2022 Sep 27.